Royal Bank of Canada
ALNY icon

Royal Bank of Canada’s Alnylam Pharmaceuticals ALNY Stock Holding History

Royal Bank of Canada’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$15K – 6994
2024
Q1 		$15K Buy
+100
New +$16.7K ﹤0.01% 6023
2021
Q1 		– Sell
-60,000
Closed -$7.8M – 7392
2020
Q4 		$7.8M Hold
60,000
– – ﹤0.01% 1895
2020
Q3 		$8.74M Hold
60,000
– – ﹤0.01% 1631
2020
Q2 		$8.89M Hold
60,000
– – ﹤0.01% 1568
2020
Q1 		$6.53M Hold
60,000
– – ﹤0.01% 1631
2019
Q4 		$6.91M Hold
60,000
– – ﹤0.01% 1904
2019
Q3 		$4.83M Hold
60,000
– – ﹤0.01% 2115
2019
Q2 		$4.35M Buy
+60,000
New +$4.6M ﹤0.01% 2177

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royal Bank of Canada's ALNY Position: Q1 2026 in Review

Royal Bank of Canada increased its Alnylam Pharmaceuticals (ALNY) stake by 34% in Q1 2026, buying an estimated $68.1M and bringing the position to 791,515 shares worth $262M. The position accounts for 0.05% of the portfolio, ranked #346.

Royal Bank of Canada first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Royal Bank of Canada held 791,515 shares of Alnylam Pharmaceuticals worth $262M as of Q1 2026.
  • Royal Bank of Canada bought 200,020 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $68.1M.
  • Alnylam Pharmaceuticals made up 0.05% of Royal Bank of Canada's portfolio in Q1 2026, its #346 holding.
  • Royal Bank of Canada first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.